Literature DB >> 20599444

Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells.

Daniel Abate-Daga1, Laura Garcia-Rodríguez, Lauro Sumoy, Cristina Fillat.   

Abstract

The suicide system TK/GCV is an enzyme/prodrug therapy that involves the transfer of the cDNA for the herpes simplex virus thymidine kinase gene (TK) into tumor cells which then sensitizes the cells to the non-toxic antiviral drug ganciclovir. Although extensively characterized, the suicide system TK/GCV conceals the details of its mechanism of action. In order to shed some light on this issue, we conducted experiments designed to identify key features of sensitive cells, as compared to cells that displayed reduced sensitivity to TK/GCV. Cell lines displaying different degrees of sensitivity underwent apoptotic cell death upon treatment with TK/GCV. S-phase delay, however, was almost exclusively restricted to sensitive cells and was impaired in a model of treatment-induced resistance. In this model genes with differential expression associated to induced resistance were identified. Noteworthy, two cell cycle-related genes (CCNE1 and GADD45) were functionally validated as conditioners of cellular sensitivity to TK/GCV. The relevance of cell cycle control was further demonstrated by experiments showing the association of Chk1 activation with greater TK/GCV cytotoxicity. Combination treatment with Chk1 inhibitor UCN-01 induced, in sensitive cells, an antagonistic effect on TK/GCV cytotoxicity highlighting the relevance of Chk1's activity on TK/GCV mechanism of action. These results reveal the relevance of cell cycle control pathways in the cytotoxicity induced by the TK/GCV system identifying candidate genes as conditioners of TK/GCV sensitivity. Moreover it points out, for the first time at Chk1 activation as a key factor to mediate TK/GCV cytotoxicity.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599444     DOI: 10.1016/j.bbamcr.2010.06.009

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

Review 1.  GADD45 proteins: central players in tumorigenesis.

Authors:  R E Tamura; J F de Vasconcellos; D Sarkar; T A Libermann; P B Fisher; L F Zerbini
Journal:  Curr Mol Med       Date:  2012-06       Impact factor: 2.222

2.  Suicide Gene Therapy for Cancer - Current Strategies.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Antonios Sakkas; Lonny Yarmus; Haidong Huang; Qiang Li; Lutz Freitag; Konstantinos Zarogoulidis; Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2013-08-09

3.  Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response.

Authors:  Seung-Pil Shin; Hye-Hyun Seo; Jae-Hun Shin; Hyung-Bae Park; Dong-Pyo Lim; Hyeon-Seok Eom; Yong-Soo Bae; In-Hoo Kim; Kyungho Choi; Sang-Jin Lee
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

4.  Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.

Authors:  Joanna D Holbrook; Joel S Parker; Kathleen T Gallagher; Wendy S Halsey; Ashley M Hughes; Victor J Weigman; Peter F Lebowitz; Rakesh Kumar
Journal:  J Transl Med       Date:  2011-07-25       Impact factor: 5.531

5.  Unrepairable DNA double-strand breaks initiate cytotoxicity with HSV-TK/ganciclovir.

Authors:  B Ladd; J J O'Konek; L J Ostruszka; D S Shewach
Journal:  Cancer Gene Ther       Date:  2011-08-26       Impact factor: 5.987

Review 6.  Stem cell based gene therapy in prostate cancer.

Authors:  Jae Heon Kim; Hong Jun Lee; Yun Seob Song
Journal:  Biomed Res Int       Date:  2014-07-10       Impact factor: 3.411

Review 7.  Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.

Authors:  Muhammad Khan; Zhihong Zhao; Sumbal Arooj; Yuxiang Fu; Guixiang Liao
Journal:  Front Immunol       Date:  2020-11-19       Impact factor: 7.561

8.  AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.

Authors:  Maria Victoria Maliandi; Ana Mato-Berciano; Luciano Sobrevals; Gaël Roué; Anabel José; Cristina Fillat
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

9.  Pancreatic cancer gene therapy: from molecular targets to delivery systems.

Authors:  Cristina Fillat; Anabel Jose; Xavier Bofill-Deros; Ana Mato-Berciano; Maria Victoria Maliandi; Luciano Sobrevals
Journal:  Cancers (Basel)       Date:  2011-01-18       Impact factor: 6.639

Review 10.  Immunotherapy and gene therapy as novel treatments for cancer.

Authors:  Martha Montserrat Rangel-Sosa; Estuardo Aguilar-Córdova; Augusto Rojas-Martínez
Journal:  Colomb Med (Cali)       Date:  2017-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.